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BACKGROUND
Proton magnetic resonance studies of stroke carried out
to date concerned mainly the changes present in the
ischemic focus itself. Typical abnormalities include the
decreased level of N-acetylaspartate (NAA) and increased
concentration of lactates (Lac) [1,2]. These changes
reflect neuronal deficits (NAA) and phagic activity of
macrophages within the area of malacia [3,4]. They are,
however, the final effect of a cascade of unfavorable
events, initiated, among others, by an increase of extra-
cellular glutamate level, activation of NMDA receptors,
and calcium inflow into the cells. Compensatory increase
of gamma-aminobutyric acid (GABA) concentration
occurs in response to the excesive accumulation of the
glutamates in the extracellular space, to inhibit their
excitotoxic effect [5]. Thus, enhancing the GABA-ergic
system function seems to be one of the possible ways of
neuroprotection after a cerebral insult [6].
The course of stroke depends on the equilibrium
between the system of excitatory and inhibitory neuro-
transmitters. Lower plasma concentration of gamma-
aminobutyric acid and higher concentration of gluta-
mate was associated with worsening and exacerbation of
the neurological deficits in lacunar strokes [7].
GABA is a primary neurotransmitter and modulator
secreted by all migrating cells during the period of
brain development. Precursor neuronal cells, synthesiz-
ing GABA, are then influenced by diffrentiating sub-
stances and transformed into glutaminergic, monoamin-
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Summary
Background: Experimental studies have suggested that ischemic stroke causes increment in extracellular level of gamma-aminobutyric
acid in response to excessive glutamate concentration and function. The increased GABA concentration is followed by subsequent
inhibition of GABA synthesis, thus leading to GABA-ergic dysfunction. Enhancing GABA function seems to be a way of neuroprotec-
tion after cerebral insult.
Animal models have shown there is overactivity of excitatory neurotransmitters and decreased tone of GABA-ergic system also in the
remote neocortical regions. Data concerning changes in brain areas outside the stroke lesion in humans is sparse. These regions could
be possible targets for therapeutic intervention. Progress in imaging techniques enables separation of a great number of chemical com-
pounds. Our aim was to assess GABA levels outside the ischemic lesion by means of proton magnetic resonance spectroscopy (1H
MRS).
Material and Methods: The study compared 31 patients with first-ever ischemic stroke and 20 healthy subjects. Single voxel H1-
MRS was performed to measure GABA/Cr ratios in structurally normal prefrontal regions, distant from the stroke lesion. The amonut
of the remaining metabolites (NAA, Cho, mI, Glx) was also estimated. Patients underwent the examination in the acute phase of the
disease and 3 months later.
Results: Both early after stroke and more than 3 months later, the patients had lower GABA levels. However, during the second
examination, this difference was evident only in the frontal cortex ipsilateral to the lesion.
Conclusions: These findings suggest that GABA function is decreased outside the infarct. Further studies are needed for confirma-
tion of the results and elucidation of the possible role of GABA alterations in stroke recovery and therapy.
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ergic, cholinergic or peptidergic neuronal phenotypes.
However, even mature, differentiated neuronal or glial
cell phenotypes are still characterized by measurable
activity of glutamic acid decarboxylase (a GABA-synthe-
sizing enzyme) and GABA [8]. GABA-expressing cells
are common in the whole nervous system, but they are
especially numerous in the telencephalic structures –
particularly in the cerebral cortex [9]. They form neu-
ronal networks influencing the function of other trans-
mitter systems [10]. Animal model studies have demon-
strated that focal ischemia, in addition to local changes,
causes a disturbance of the equilibrium between the glu-
taminergic and GABA-ergic systems in neocortical areas
remote from the ischemic focus in the hemisphere ipsi-,
as well as contralateral to the lesion. This disturbance
involves an increase of NMDA and decrease of GABA
receptors density [11].
Little is known about the distant changes in the course
of stroke in humans. Such knowledge would be impor-
tant, because the unaffected cerebral tissue is the target
site of pharmacological agents used in treatment. 1H
MRS is a technique allowing non-invasive in vivo assess-
ment of biochemical changes in the particular brain
region. The advances in spectroscopy (better resolution
of the spectrum), have made it possible to identify more
and more chemical compounds, including gamma-
aminobutyric acid bands.
The aim of the study was to assess the changes of GABA
levels in brain areas distant from the ischemic focus and
rich in GABA-producing neurons – in the neocortex, by
means of 1H MRS technique. The amonut of the remain-
ing metabolites (NAA, Cho, mI, Glx) was also estimated.
MATERIAL AND METHODS
The patients with ischemic stroke treated in the Stroke
Unit, Colegium Medicum Jagielonian University Depart-
ment of Neurology, in Cracow from January 2001 to
February 2002 were included in the study. The inclusion
criteria were as follows: the first-ever ischemic stroke,
defined according to WHO criteria [12], no symptoms of
cerebellum and brain stem damage or symptoms sug-
gesting ischemia in the area supplied by the anterior
cerebral artery both in neurological assessment and in
CT. The following exclusion criteria were applied: signs
of intracerebral hemorrhage in cranial CT, the history of
previous depression, psychotic disorders, alcoholism,
dementive syndromes, treatment with psychoactive
drugs within one month before admission to hospital,
poor clinical condition or other contraindications mak-
ing it impossible to perform MRI.
The control group consisted of 20 sex- and age-matched
healthy volunteers.
Magnetic resonance and proton spectroscopy
The patients were subjected to MR and 1H MRS in the
acute phase of the disease and after a few months using
Signa GE Horizon 1.5T equipment, Dept. of Radiology,
CMUJ. Transverse section T1- (TR-500 ms, TE-12, 6
ms) and T2-weighted (TR-5000 ms, TE- 100 ms) images
were acquired. The slice thickness was 6 mm, the gap
between slices 2 mm. 1H MRS spectra were obtained
using single voxel localized spectroscopy method.
The localization of the region of interest (ROI) was deter-
mined on the basis of T1-weighted MR images. Each
time, ROI was placed subsequently in the right, and then
in the left hemisphere, in the anterior part of the frontal
lobe, in the prefrontal area, near the midline, in appar-
ently normal area unaffected by ischemia. It was localized
in the image, in which the central or upper part of the
lateral ventricle was still visible (Figure 1). The region of
interest, of ca. 6 cm3 mean volume, included the cortex of
the frontal lobe and the subcortical white matter. The
spectrum was recorded using point resolved spectroscopy
(PRESS) impulse sequence (TR=1500 ms, TE=35 ms).
A B
Figure 1A,B. Localization of the region of interest in T1-weighted images.
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The number of acquisitions was 256. Prior to spectrum
recording, an automatic procedure increasing the field
homogeneity within the patient’s head and the selected
region of interest was applied. The signal of water was
suppressed using chemical shift selective sequence
(CHESS). The whole procedure of the examination was
automatic and resulted in the total examination time of 3
min 42 sec. The spectrum was processed using SAGE
software. The bands corresponding to glutamates Glx
(2.1–2.5 ppm), GABA (2.3 ppm), creatine Cr (3.03 ppm),
N-acetylaspartate (NAA) – 2.02 ppm, choline (Cho) – 3.2
ppm and myoinositol (mI) 3.5–3.65 ppm were assessed in
the spectrum.
The proportions of NAA, Cho, mI, Glx and GABA to
creatine were analyzed. The level of creatine was adopt-
ed as a stable internal standard.
Statistical analysis
Because of asymmetrical distribution of most analyzed
parameters, Mann-Whitney U test was used. The analy-
sis was carried out using STATISTICA 5, 97 software
package. The values are expressed in the tables as means
±standard deviation. The analysis of metabolite levels in
the prefrontal region of the hemisphere ipsi- and con-
tralateral to the infarct was carried out comparing the
values obtained in the patient group with measurements
from both hemispheres obtained in control subjects (40
measurements). Earlier comparison of the values of
metabolite to creatine ratios for particular metabolites in
the right and left hemispheres in the control group
demonstrated no significant differences (Wilcoxon test).
RESULTS
The first examination in the acute phase of stroke (9±2
days from the onset of the disease) was performed in 31
patients, including 15 women and 16 men aged from 45
to 80 years; mean age: 62.9 (±9) years. The next exami-
nation was performed after about 110 (±30) days in 27
patients, (15 women and 12 men); aged from 45 to 80
years; mean age: 63 (±9) years.
The patients who were not examined the second time
were three men with the infarct located in the right
hemisphere and one man with the infarction in the left
hemisphere. The reason for failure to perform the
examination was deterioration of the patients’ condition
providing contraindication for transport in two cases
and resignation from participation in the study in the
remaining two.
Stroke patients Control group Statistical significance
NAA/Cripsilateral
NAA/Crcontralateral
Cho/Cripsilateral
Cho/Crcontralateral
mI/Cripsilateral
mI/Crcontralateral
GABA/Cripsilateral
GABA/Crcontralateral
Glx/Cripsilateral
Glx/Crcontralateral
1.7981±0.4938
1.6256±0.3876
0.9275±0.2287
0.8838±0.1889
0.9946±0.4624
0.8479±0.3026
0.4612±0.2506
0.4134±0.1367
0.4711±0.2228
0.4296±0.1335
1.6890±0.2770
1.6890±0.2770
0.9657±0.1836
0.9657±0.1836
0.8656±0.1886
0.8656±0.1886
0.5373±0.1874
0.5373±0.1874
0.4655±0.1855
0.4655±0.1855
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
p<0.03
p<0.004
n.s.
n.s.
Table 1. Comparison of particular metabolite levels during the first spectroscopy, in the prefrontal region ipsi- and contralateral to the ischemic focus,
in stroke patients and control subjects (40 measurements).
Three months after the onset of the disease, stroke patients were still characterized by lower GABA/Cr values in both prefrontal regions (both in the hemisphere ipsilateral
to the ischemic focus and in the contralateral one); however, the difference reached statistical significance for the ipsilateral area only (Table 2). The values of NAA/Cr,
Cho/Cr, mI/Cr and Glx/Cr did not differ significantly on both examinations
Stroke patients Control group Statistical significance
NAA/Cripsilateral
NAA/Crcontralateral
Cho/Cripsilateral
Cho/Crcontralateral
mI/Cripsilateral
mI/Crcontralateral
GABA/Cripsilateral
GABA/Crcontralateral
Glx/Cripsilateral
Glx/Crcontralateral
1.5700±0.2962
1.6959±0.3791
0.9031±0.1564
0.9169±0.2135
0.9033±0.2798
0.8494±0.2662
0.4072±0.1898
0.4744±0.1722
0.4305±0.1682
0.4339±0.1169
1.6890±0.2770
1.6890±0.2770
0.9657±0.1836
0.9657±0.1836
0.8656±0.1886
0.8656±0.1886
0.5373±0.1874
0.5373±0.1874
0.4655±0.1855
0.4655±0.1855
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
p<0.004
n.s.
n.s.
n.s.
Table 2. Comparison of particular metabolite levels during the second spectroscopy, in the prefrontal region ipsi- and contralateral to the ischemic
focus, in stroke patients and control subjects (40 measurements).
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The control group consisted of 20 healthy volunteers (9
women and 11 men). The age ranged from 49 to 79
years, mean 59.6 ((9.3) years.
The infarct was located in the right hemisphere in 15,
and in the left in 16 cases. It involved only subcortical
areas in 17 patients, only cortical areas in 3, and in 9
both the cortex and the subcortical areas.
At the time of the first examinations, the stroke patients
had lower GABA/Cr values in both prefrontal regions
(both ipsi- and contralateral to the ischemic focus)
(Table 1).
Three months after the onset of the disease, stroke
patients were still characterized by lower GABA/Cr val-
ues in both prefrontal regions (both in the hemisphere
ipsilateral to the ischemic focus and in the contralateral
one); however, the difference reached statistical signifi-
cance for the ipsilateral area only (Table 2). The values
of NAA/Cr, Cho/Cr, mI/Cr and Glx/Cr did not differ sig-
nificantly on both examinations.
Example of the obtained spectrum is presented in
Figure 2. (A,B – patients group, C – control group.
DISCUSSION
Considering the results obtained with magnetic reso-
nance spectroscopy method, it should be emphasized
that there are certain limitations. The region of interest
included the cortex of the frontal lobe, and the mean
measurement volume was ca. 6 cm3. Such volume was
dictated by the intention to include predominantly grey
matter in the investigated area and to ensure the best
possible field homogeneity in the analyzed region.
However, reduction of the volume of the analyzed area
is associated with a decrease of the signal to noise ratio.
Thus, it is possible that reduction of the area of interest
affected the spectrum quality, especially in view of the
fact that because of automatic measurement procedure
and the patients’ condition, which often required short-
ening of the examination time, the possible signal loss
could not be compensated by prolonged time of the
examination.
Whereas the determination of resonance lines rather
does not raise any doubt in case of creatine, N-acetylas-
partate, myoinositol and choline, the analysis of gluta-
mate, glutamine and gamma-aminobutyric acid signals is
much less reliable. The signal intensity of these com-
pounds is relatively low, which results in low signal to
noise ratios. Additionally, these substances are visualized
as complex multiplets [13], which makes the assignment
of resonance lines difficult. The GABA signal was
assigned at 2.3 ppm. The signal of gamma-aminobutyric
acid C4 functional group is localized at 3.03 ppm [15–17];
however, it is not visible there because of the overlapping,
of much stronger creatine signal. As the method of GABA
measurement described by Goddard et al. and Sanacora
et al. [16,17], using J-editing impulse sequence, was not
available in the present study, only the signal intensity for
CH2 GABA group localized in the spectrum at 2.3 ppm
was determined. Glutamate and glutamine are difficult to
separate in spectrum obtained using 1.5 T field intensity
and therefore marked as a common Glx peak. Antuono
et al. investigated Glx resonance signal in 0.5 T field, with
A
B
C
Figure 2A–C. Spectrum obtained with PRESS sequence.
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Glx β and γ singlet best visible at 2.35 ppm [14]. The pre-
sent study utilized a standard 1.5 T magnet, in which the
Glx β and a signal is not visualized as such a distinct peak
as obtained with the technique proposed by the Wis-
consin team. Although in proton spectroscopy spectrum
the resonance line for glutamate/glutamine is also local-
ized in the 3.75–3.8 area [15], in order to simplify the
comparisons, one resonance line corresponding to Glx β
– localized at 2.1–2.5 ppm (ca. 2.2 ppm) was analyzed in
the present study [15]. Considering all the above limita-
tions, it should be emphasized that the obtained results
can be treated as preliminary and require confirmation
with more accurate techniques.
Stroke patients had lower GABA/Cr values in both pre-
frontal regions (both ipsi- and contralateral to the ischemic
focus). Also at the time of the second examination, the
patient group was characterized by parameters indicating
decreased GABA levels. No differences in the ratios of the
remaining metabolites to creatine were observed.
The studies carried out to date have demonstrated that an
ischemic event leads to pathologic increase of excitotoxic
amino acid activity, which initiates a cascade of unfavor-
able events leading to cell death [5]. This sequence of
unfavorable phenomena has been suggested to be depen-
dent on the equilibrium between the excitatory and
inhibitory mechanisms [18]. Gamma-aminobutyric acid,
antagonizing the effect of glutamates, is the main inhibito-
ry neurotransmitter [19]. It has been demonstrated that
stimulation of GABA-ergic transmission with clomethia-
zole or its analogs acting directly on GABAA receptor com-
plex chloride channels exerts a neuroprotective effect and
inhibits glutamate release caused by ischemia [20].
Tiagabine, a selective GABA uptake inhibitor, exerts a
similar effect [21]. Animal model experiments have
demonstrated that accumulation of GABA in extracellular
space occurs in response to cerebral tissue ischemia [5,19],
probably in order to reduce the effect of excitotoxic amino
acid activity. Nevertheless, the consequence of this rapid
GABA accumulation is a decrease of production and
release of this neurotransmitter [5], and, consequently,
reduction of GABA-ergic transmission.
The processes described above take place at the
ischemic site. Experiments with focal ischemia in mice
have demonstrated that persistent disturbances of the
equilibrium between the excitatory (increase of gluta-
minergic activity) and inhibitory system (decrease of
GABA-ergic activity) are observed also in the regions
remote from the ischemic focus [11].
In this context, the decreased level of GABA in stroke
patients seems to be a consistent finding. The first exami-
nations were performed on the average 10 days after the
stroke, i.e. after the period of rapid increase of gamma-
aminobutyric acid concentration in extracellular space.
The obtained results may reflect the GABA synthesis inhi-
bition phase and disturbances of GABA-ergic transmis-
sion also outside the ischemic focus. However, as long as
it is possible to explain low GABA levels in the acute
phase of stroke, it is unclear whether the persistence of
such low values several months after the onset of the dis-
ease should be attributed to sustained suppression of the
synthesis. No increase of glutamate level, as it could be
expected, was observed. As the fluctuations of glutamate
levels precede the changes of GABA concentrations, the
selected time of the examination might already not have
allowed to demonstrate such fluctuations.
The mechanisms of post-stroke function restoration
involve, among others, the reorganization of spared
neuronal circuits, which leads to extended activation
and recruitment of additional cortical areas during the
motor task performance [22]. The presented study has
demonstrated that changes which may be important for
remission or persistence of the neurological deficits take
place even in the regions regarded as unaffected on the
basis of morphological images. It has been suggested
that the predominance of the glutaminergic system
(imbalance between GABA and glutamates) observed
after focal ischemia may be associated with hyperex-
citability and occurrence of focal epileptic activity [11].
Further studies are needed to answer the questions
whether the abnormalities observed outside the
ischemic focus affect the process of post-stroke rehabili-
tation, as well as whether, and to what extent, they can
become a target of pharmacological interventions.
CONCLUSIONS
Stroke patients demonstrate, in comparison to the control
group, decreased levels of gamma-aminobutyric acid in
the cerebral areas outside the infarct. This may reflect the
impact of the ischemic focus on the remote brain regions,
probably resulting in the inhibition of GABA production.
Further studies are needed to confirm these results.
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